Pamela Pavco - RXi Pharmaceuticals Chief Devel. Officer
Executive
Ms. Pamela Pavco, Ph.D. is a Chief Development Officer of RXI Pharmaceuticals Corporationrationration. Prior to this, Dr. Pavco served as our Senior Vice President of Pharmaceutical Development from September 24, 2011 until April 2012. From March 2007 to September 24, 2011, she served as the Vice President of Pharmaceutical Development of Galena Biopharma, Inc. Dr. Pavco has over 20 years of research and development experience in oligonucleotides. Dr. Pavco was Senior Director, Research and Development Project Management at Sirna Therapeutics, Inc., from 2002 until 2006, when it was acquired by Merck Co., Inc. for 1.1 billion. While at Sirna, she was responsible for the discovery research and development of Sirna027, the first chemically modified siRNA to enter clinical trials. Dr. Pavco also managed Sirnas alliance with Allergan, Inc. that was initiated to continue discovery research in the area of ophthalmology and take Sirna027 forward into Phase 2 clinical studies. While at Sirna, Dr. Pavco served in various additional capacities, including Director of Biology Research and Director of Pharmacology and she also managed numerous corporate collaborations and internal programs focusing on the development of therapeutic oligonucleotides in the fields of oncology, antiangiogenesis, hepatitis, respiratory disease and Huntingtons disease. Dr. Pavco has authored numerous scientific articles and contributed to approximately 58 patents and patent applications in the oligonucleotide therapeutics field since 2012.
| Age | 57 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Phone | 508-767-3861 |
| Web | http://www.rxipharma.com |
RXi Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (96.79) % which means that it has lost $96.79 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (294.79) %, meaning that it created substantial loss on money invested by shareholders. RXi Pharmaceuticals' management efficiency ratios could be used to measure how well RXi Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jeff Miller | Parker Hannifin | N/A | |
| Kin MBA | HUTCHMED DRC | 47 | |
| Selina Zhang | HUTCHMED DRC | N/A | |
| Qingmei Wang | HUTCHMED DRC | 61 | |
| Roger Theodoredis | Chipotle Mexican Grill | 65 | |
| Kekin Ghelani | Summit Materials | 50 | |
| Scott Boatwright | Chipotle Mexican Grill | 51 | |
| David Ng | HUTCHMED DRC | N/A | |
| Jason Kilgore | Summit Materials | 49 | |
| Hong Chen | HUTCHMED DRC | 54 | |
| Julio DaSilva | Summit Materials | N/A | |
| Robin Davenport | Parker Hannifin | 62 | |
| Mark Crumpacker | Chipotle Mexican Grill | 53 | |
| D Eskenazi | Chipotle Mexican Grill | 52 | |
| Marissa Andrada | Chipotle Mexican Grill | 53 | |
| Cynthia CFA | Chipotle Mexican Grill | N/A | |
| Christopher Brandt | Chipotle Mexican Grill | 55 | |
| Charles DePriest | Summit Materials | 51 | |
| Michael OHara | Parker Hannifin | N/A | |
| Laurie Schalow | Chipotle Mexican Grill | 56 | |
| Trent Musso | Summit Materials | N/A | |
Management Performance
| Return On Equity | -294.79 | |||
| Return On Asset | -96.79 |
RXi Pharmaceuticals Leadership Team
Elected by the shareholders, the RXi Pharmaceuticals' board of directors comprises two types of representatives: RXi Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RXi. The board's role is to monitor RXi Pharmaceuticals' management team and ensure that shareholders' interests are well served. RXi Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RXi Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Geert Cauwenbergh, President CEO, Director | ||
| Robert Bitterman, Director | ||
| Pamela Pavco, Chief Devel. Officer | ||
| Keith Brownlie, Director | ||
| Jonathan Freeman, Independent Director | ||
| Gerrit Dispersyn, Chief Development Officer | ||
| Curtis Lockshin, Director | ||
| Paul Dorman, Independent Director | ||
| Alexey Eliseev, Chief Business Officer | ||
| Tamara McGrillen, IR Contact Officer |
RXi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RXi Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -294.79 | |||
| Return On Asset | -96.79 | |||
| Current Valuation | (1.77 M) | |||
| Shares Outstanding | 18.16 M | |||
| Shares Owned By Insiders | 3.78 % | |||
| Shares Owned By Institutions | 10.08 % | |||
| Number Of Shares Shorted | 814.04 K | |||
| Price To Earning | (0.54) X | |||
| Price To Book | 0.84 X | |||
| Price To Sales | 39.20 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards RXi Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, RXi Pharmaceuticals' short interest history, or implied volatility extrapolated from RXi Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in RXi Stock
If you are still planning to invest in RXi Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RXi Pharmaceuticals' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| CEOs Directory Screen CEOs from public companies around the world |